How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Lower Costs, More Transparency Act of 2026
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 9393 (Lower Costs, More Transparency Act of 2026) -In support of the Lower Cost, More Transparency Act as this bill will require hospitals, labs, and image providers to make price information publicly available and will help reign in Pharmacy Benefit Managers (PBMs).
FRONT Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2026 · third_quarter · Q3
H.R. 9393 (Lower Costs, More Transparency Act of 2026) -In support of the Lower Cost, More Transparency Act as this bill will require hospitals, labs, and image providers to make price information publicly available and will help reign in Pharmacy Benefit Managers (PBMs).
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2026 · second_quarter · Q2
Source: Senate LDA
Medication Affordability and Patent Integrity Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Ensuring Timely Access to Generics Act of 2025
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
PBM Price Transparency and Accountability Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
S.3345 - PBM Price Transparency and Accountability Act - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1492 (EPIC Act) - Asking members to co-sponsor HR 1492 which fixes the Inflation Reduction Act's small molecule "pill penalty" to ensure continued R&D investments into small molecule medicines.
PBM Reform Act of 2025
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R.4317 (PBM Reform Act) - Asking house members to co-sponsor HR 4317 which would ban spread pricing in Medicaid, boost transparency, delinks PBM compensation in Part D, and strengthens CMS oversight of PBM Contracts. H.R. 5256 (Medicare Access to Rural Anesthesiology of 2023) 340B Access Act - Asking house members to co-sponsor 340B Access Act which would make 340B a true safety-net program for patients by ensuring prescriptions are offered to patients at a discount, update and strengthen eligibility requirements, address standards for 340B child sites and subgrantee eligibility.
340B ACCESS Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R.4317 (PBM Reform Act) - Asking house members to co-sponsor HR 4317 which would ban spread pricing in Medicaid, boost transparency, delinks PBM compensation in Part D, and strengthens CMS oversight of PBM Contracts. H.R. 5256 (Medicare Access to Rural Anesthesiology of 2023) 340B Access Act - Asking house members to co-sponsor 340B Access Act which would make 340B a true safety-net program for patients by ensuring prescriptions are offered to patients at a discount, update and strengthen eligibility requirements, address standards for 340B child sites and subgrantee eligibility.
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 2880 Protecting Patients Against PBM Abuses Act - Discuss updated jobs study, MFN price control and PBM Reform.
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act.
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
DRUG Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
Negative Impacts of Expanding TRIPS - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health. H.R. 6283 DRUG-ACT - Request to co-sponsor the Drug-Act, vote to move to markup in committee and include in the next spending bill. MARCH-IN Congressional Letter - Asking Congressional Members to sign on to letter to President Biden opposing the recent NIST guidance. Proposed guidance attempts to change the landmark Bayh-Dole Act without the consent of Congress. The draft framework will hamstring U.S. innovation to the advantage of competitors and adversaries.
DRUG Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.
DRUG Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Biosimilar Red Tape Elimination Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Medication Affordability and Patent Integrity Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
Inflation Reduction Act (IRA) - Opposing Expansion of IRA Bill's Drug Coverage. While understanding the intention to provide wider access to affordable medications, we believe this proposed expansion could have unintended negative consequences on employment with the prescription drug industry. Protecting Patients Against PBM Abuses Act (H.R. 2880) - Urging support of H.R. 2880. 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) - Oppose legislation to expand upon the recent bipartisan language in the draft to reintroduce the concept of "Reasonable Pricing" requirements.
Reward Work Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
No Free TRIPS Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
No Free TRIPS Act (H.R. 3858) - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health.
HELP Copays Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
Prescription Pricing for the People Act of 2023
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation.
SMART Prices Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
Pharmacy Benefit Manager Transparency Act of 2023
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation.
Infrastructure Investment and Jobs Act
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Infrastructure Investment and Jobs Act
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Infrastructure Investment and Jobs Act
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
To amend the Internal Revenue Code of 1986 to repeal the limitation on the cover over of distilled spirits taxes to the Virgin Islands and Puerto Rico.
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
To amend the Internal Revenue Code of 1986 to repeal the limitation on the cover over of distilled spirits taxes to the Virgin Islands and Puerto Rico.
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Infrastructure Investment and Jobs Act
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Infrastructure Investment and Jobs Act
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Patient Protection and Affordable Care Enhancement Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Patient Protection and Affordable Care Enhancement Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Patient Protection and Affordable Care Enhancement Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 3 AN ACT To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Firm: DAVE KOLBE CONSULTING
H.R. 3 AN ACT To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
Tribal Labor Sovereignty Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
S. 63 - Tribal Labor Sovereignty Act of 2017 - This bill amends the National Labor Relations Act (NLRA) to exclude Native American tribes and tribal enterprises and institutions on tribal land from requirements for employers under the NLRA. (Currently under the NLRA, employers may not engage in unfair labor practices and must allow employees to form unions, engage in collective bargaining, and take collective action.)
VA Accountability First Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 1259 - VA Accountability First Act of 2017 S. 1094 - Department of Veterans Affairs Accountability and Whistleblower Protection Act of 2017 H.R. 1461 - VET Protection Act of 2017 Use of PLAs in VA facility construction.
VET Protection Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 1259 - VA Accountability First Act of 2017 S. 1094 - Department of Veterans Affairs Accountability and Whistleblower Protection Act of 2017 H.R. 1461 - VET Protection Act of 2017 Use of PLAs in VA facility construction.
Dream Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 4253, the American Promise Act of 2017, legislation to provide for certain protections for aliens granted temporary protected status or deferred enforced departure; entire bill. S. 2144, the SECURE Act, legislation to provide a process for granting lawful permanent resident status to aliens from certain countries who meet specified eligibility requirements; entire bill. S. 1615, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States. H.R. 3440, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States.
American Promise Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 4253, the American Promise Act of 2017, legislation to provide for certain protections for aliens granted temporary protected status or deferred enforced departure; entire bill. S. 2144, the SECURE Act, legislation to provide a process for granting lawful permanent resident status to aliens from certain countries who meet specified eligibility requirements; entire bill. S. 1615, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States. H.R. 3440, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States.
Department of Veterans Affairs Accountability and Whistleblower Protection Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 1259 - VA Accountability First Act of 2017 S. 1094 - Department of Veterans Affairs Accountability and Whistleblower Protection Act of 2017 H.R. 1461 - VET Protection Act of 2017 Use of PLAs in VA facility construction.
Dream Act of 2017
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 4253, the American Promise Act of 2017, legislation to provide for certain protections for aliens granted temporary protected status or deferred enforced departure; entire bill. S. 2144, the SECURE Act, legislation to provide a process for granting lawful permanent resident status to aliens from certain countries who meet specified eligibility requirements; entire bill. S. 1615, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States. H.R. 3440, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States.
SECURE Act
Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS · Firm: DAVE KOLBE CONSULTING
H.R. 4253, the American Promise Act of 2017, legislation to provide for certain protections for aliens granted temporary protected status or deferred enforced departure; entire bill. S. 2144, the SECURE Act, legislation to provide a process for granting lawful permanent resident status to aliens from certain countries who meet specified eligibility requirements; entire bill. S. 1615, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States. H.R. 3440, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States.
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2026 · first_quarter · Q1
S.3345 - PBM Price Transparency and Accountability Act - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2025 · third_quarter · Q3
H.R.4317 (PBM Reform Act) - Asking house members to co-sponsor HR 4317 which would ban spread pricing in Medicaid, boost transparency, delinks PBM compensation in Part D, and strengthens CMS oversight of PBM Contracts. H.R. 5256 (Medicare Access to Rural Anesthesiology of 2023) 340B Access Act - Asking house members to co-sponsor 340B Access Act which would make 340B a true safety-net program for patients by ensuring prescriptions are offered to patients at a discount, update and strengthen eligibility requirements, address standards for 340B child sites and subgrantee eligibility.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2025 · second_quarter · Q2
H.R. 2880 Protecting Patients Against PBM Abuses Act - Discuss updated jobs study, MFN price control and PBM Reform.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2025 · first_quarter · Q1
H.R. 1492 (EPIC Act) - Asking members to co-sponsor HR 1492 which fixes the Inflation Reduction Act's small molecule "pill penalty" to ensure continued R&D investments into small molecule medicines.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2024 · fourth_quarter · Q4
H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2024 · third_quarter · Q3
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2024 · second_quarter · Q2
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2024 · first_quarter · Q1
Negative Impacts of Expanding TRIPS - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health. H.R. 6283 DRUG-ACT - Request to co-sponsor the Drug-Act, vote to move to markup in committee and include in the next spending bill. MARCH-IN Congressional Letter - Asking Congressional Members to sign on to letter to President Biden opposing the recent NIST guidance. Proposed guidance attempts to change the landmark Bayh-Dole Act without the consent of Congress. The draft framework will hamstring U.S. innovation to the advantage of competitors and adversaries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2023 · fourth_quarter · Q4
No Free TRIPS Act (H.R. 3858) - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health.
Filing targets: HOUSE OF REPRESENTATIVES
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2023 · fourth_quarter · Q4
Expediting the construction permitting process. No specific Bill number.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2023 · third_quarter · Q3
Inflation Reduction Act (IRA) - Opposing Expansion of IRA Bill's Drug Coverage. While understanding the intention to provide wider access to affordable medications, we believe this proposed expansion could have unintended negative consequences on employment with the prescription drug industry. Protecting Patients Against PBM Abuses Act (H.R. 2880) - Urging support of H.R. 2880. 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) - Oppose legislation to expand upon the recent bipartisan language in the draft to reintroduce the concept of "Reasonable Pricing" requirements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2023 · second_quarter · Q2
Expediting the construction permitting process.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2023 · second_quarter · Q2
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2023 · first_quarter · Q1
S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation.
Filing targets: SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2022 · fourth_quarter · Q4
Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization. Waiver of Certain Obligations under the WTO Agreement on Trade Related Aspects of Intellectual Property Rights for COVID-19 to also cover Therapeutics and Diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2022 · third_quarter · Q3
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2022 · third_quarter · Q3
Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization. Waiver of Certain Obligations under the WTO Agreement on Trade Related Aspects of Intellectual Property Rights for COVID-19 to also cover Therapeutics and Diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2022 · second_quarter · Q2
Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2022 · second_quarter · Q2
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2022 · first_quarter · Q1
Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2022 · first_quarter · Q1
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2021 · fourth_quarter · Q4
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Filing targets: SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2021 · fourth_quarter · Q4
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Filing targets: HOUSE OF REPRESENTATIVES
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2021 · third_quarter · Q3
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2021 · third_quarter · Q3
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Filing targets: SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2021 · second_quarter · Q2
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Opposing the price controls and protecting intellectual properties.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2021 · first_quarter · Q1
Merchant Marine Act of 1920 (The Jones Act) - Ensuring that all construction of offshore wind generation and ships, be U.S. built, and owned and crewed by U.S. citizens.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2021 · first_quarter · Q1
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2020 · fourth_quarter · Q4
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2020 · third_quarter · Q3
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2020 · second_quarter · Q2
H.R. 1425 - Affordable Care Act (ACA) Stabilization Legislation - Opposing the price controls contained in the ACA Stabilization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2020 · first_quarter · Q1
No specific bill numbers - Discussed infrastructure issues and its impact on the labor movement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2020 · first_quarter · Q1
H.R. 3 AN ACT To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2019 · fourth_quarter · Q4
H.R. 3 AN ACT To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2019 · fourth_quarter · Q4
No specific bill numbers - Discussed infrastructure issues and its impact on the labor movement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2019 · third_quarter · Q3
Transportation Infrastructure Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2019 · third_quarter · Q3
Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2019 · second_quarter · Q2
Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2019 · second_quarter · Q2
Apprenticeship and Training Standards
Transportation Infrastructure Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2019 · first_quarter · Q1
Medicare Part D Donut Hole Prescription Drug Coverage Gap
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2019 · first_quarter · Q1
Native American Training Program Funding Appropriations
Transportation Infrastructure Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2018 · fourth_quarter · 4A
Native American Training Program Funding Appropriations
Transportation Infrastructure Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2018 · fourth_quarter · Q4
Medicare Part D Donut Hole - Prescription Drug Coverage Gap
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2018 · fourth_quarter · Q4
Medicare Part D Donut Hole - Prescription Drug Coverage Gap
Native American Training Program Funding Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2018 · third_quarter · 3A
Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2018 · third_quarter · Q3
Discussed Native American Training Programs
Filing targets: Interior, Dept of (DOI)
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2018 · second_quarter · Q2
Met with the Dept. of Energy to discuss clean coal generation and technology. No specific Bill was discussed.
Filing targets: Energy, Dept of
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2018 · first_quarter · Q1
S. 63 - Tribal Labor Sovereignty Act of 2017 - This bill amends the National Labor Relations Act (NLRA) to exclude Native American tribes and tribal enterprises and institutions on tribal land from requirements for employers under the NLRA. (Currently under the NLRA, employers may not engage in unfair labor practices and must allow employees to form unions, engage in collective bargaining, and take collective action.)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2017 · fourth_quarter · Q4
Encouraging electric grid reliability and advocating for changes to base load compensation rules to take into account the threat to system stability being caused by coal and nuclear plant retirement.
H.R. 4253, the American Promise Act of 2017, legislation to provide for certain protections for aliens granted temporary protected status or deferred enforced departure; entire bill. S. 2144, the SECURE Act, legislation to provide a process for granting lawful permanent resident status to aliens from certain countries who meet specified eligibility requirements; entire bill. S. 1615, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States. H.R. 3440, the Dream Act of 2017, legislation to authorize the cancellation of removal and adjustment of status of certain individuals who are long-term United States residents and who entered the United States as children; Sec. 3(b)(1)(B) regarding the cancellation of removal and adjustment of status for aliens who were younger than 18 years of age when they initially entered the United States.
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2017 · third_quarter · Q3
Medicare Part-D rebates Trade agreements Patent reform issues Prescription Drug User Fee Act (PDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2017 · second_quarter · Q2
H.R. 1259 - VA Accountability First Act of 2017 S. 1094 - Department of Veterans Affairs Accountability and Whistleblower Protection Act of 2017 H.R. 1461 - VET Protection Act of 2017 Use of PLAs in VA facility construction.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2017 · second_quarter · Q2
Medicare Part-D rebates Trade agreements Patent reform issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2017 · first_quarter · Q1
Medicare Part-D rebates Trade agreements Patent reform issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via DAVE KOLBE CONSULTING
2017 · first_quarter · RR
Pharmaceutical Industry Labor Management issues.
Pharmaceutical Industry Labor Management issues.
INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS via DAVE KOLBE CONSULTING
2017 · first_quarter · RR
Labor issues.
Filing targets: Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, SENATE